Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 21 of the 32 sources its claims cite were checked for support.

Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial

Open access

Abstract

BACKGROUND: A dysbiotic vaginal microbiome (VMB) is associated with clinical conditions such as bacterial vaginosis (BV) and an increased risk of human immunodeficiency virus (HIV-1) infection. Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility. METHODS: ACB women aged 18-49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. Feasibility was evaluated through enrolment, retention, and adherence rates, while safety and tolerability were determined by a pre- and post-treatment blood panel and reported adverse events (AEs). RESULTS: Overall, 63 ACB women were screened, 50 were enrolled and received the intervention while 41 completed the study, resulting in 80% enrollment and 82% retention rates. Overall adherence to the study protocol was high at 93%, with an adherence of 92% for RepHresh™ Pro-B™ and 97% for Estring©. A total of 88 AEs were reported by 29 participants which were mild (66/88; 75%) and largely resolved (82/88;93%) by the end of the study, with no serious AEs (SAEs) noted. In addition, a panel of safety blood markers measured pre- and post-intervention confirmed no clinically significant changes in blood chemistry or blood cell count. CONCLUSION: Overall, the administration of intravaginal estrogen and/or probiotics in pre-menopausal ACB women is feasible, safe, and well tolerated. TRIAL REGISTRATION: The trial was registered with Clinicaltrials.gov (NCT03837015) and CIHR HIV Clinical Trials (CTN308).

Overview

CoChat Summary

## TL;DR

This phase 1 randomized open-label trial in healthy premenopausal Canadian African, Caribbean, and Black (ACB) women found that 30 days of intravaginal estradiol and/or probiotics was feasible, safe, and well tolerated. Across 50 treated participants, enrollment was 80%, retention was 82%, adherence was 93%, and no serious adverse events or clinically significant blood-marker changes were seen.

## Key findings

  • Of 63 screened women, 50 were enrolled/treated and 41 completed the study, yielding an 80% enrollment rate and 82% retention rate; these met or exceeded the prespecified feasibility targets of 70% and 80%, respectively.
  • Overall adherence was 93% (probiotic adherence 92%; Estring adherence 97%); diary completion was 97% when including participants who discontinued, and sexual history questionnaire completion was 100%.
  • A total of 88 adverse events were reported by 29 participants; 66/88 (75%) were mild, 82/88 (93%) had resolved by study end, and no serious adverse events were reported.
  • Pre- vs post-intervention blood panels showed no clinically significant changes in blood chemistry, complete blood count, lipids, or immune-cell markers.

## Methods

  • Prospective, randomized, open-label, phase 1 clinical trial conducted over 30 days in healthy premenopausal ACB women aged 18–49 recruited from the Greater Toronto Area between Nov 1, 2019 and Dec 31, 2021.
  • Participants were randomized 1:1:1:1 to intravaginal estradiol (Estring, 7.5 mg/day), vaginal probiotic twice daily, Estring plus vaginal probiotic, or Estring plus oral probiotic; 50 participants formed the intention-to-treat sample.
  • Main analysis used descriptive statistics plus paired t-tests/Wilcoxon signed-rank tests for within-group changes and ANOVA/Kruskal-Wallis tests for between-group comparisons; safety was assessed using pre/post blood markers and reported adverse events.

## Limitations

  • The paper states that the sample size was small and that generalizability is constrained by this pilot phase 1 design.
  • The paper states that adherence was based mainly on self-report diaries and returned products, which does not rule out false reporting.
  • The paper states that there was no placebo arm and that the pre/post design could be confounded by factors such as diet or seasonal changes.
  • Evident from the text: participants were self-referred, so selection bias is possible.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0315576

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Participant flowchart. A flow diagram outlining study recruitment and completion rates. A total of 63 women were assessed for eligibility and 50 women received intervention. One woman was lost to follow up, four withdrew consent and an additional four were non-adherent to the study protocol. Overall, 41 women completed the study with group sizes between 9–13 participants for each study arm.
Fig 1 Participant flowchart. A flow diagram outlining study recruitment and completion rates. A total of 63 women were assessed for eligibility and 50 women received intervention. One woman was lost to follow up, four withdrew consent and an additional four were non-adherent to the study protocol. Overall, 41 women completed the study with group sizes between 9–13 participants for each study arm.CC BY · PubMed Central
Fig 2 Study design. This schematic outlines the design and study timeline used to evaluate the feasibility, safety and tolerability of administering low dose estrogen and/or a probiotic to premenopausal African, Caribbean, and Black (ACB) women. Eligible participants were randomized in a 1:1:1:1 ratio to receive one of four interventions including 1) the Estring alone 2) the Estring in combination with the probiotic L. rhamnosus GR-1 and L. reuteri RC-14 RepHresh Pro-B (administered vaginally), 3) the Estring together with the RepHresh Pro-B (administered orally) or the RepHresh (administered vaginally) alone. The duration of the intervention was 30 days with a 7-day follow up (visit 5) safety check. The study was designed to compare outcomes in each woman at baseline (visit 2) to the end of treatment (visit 4) with each participant serving as their own control.
Fig 2 Study design. This schematic outlines the design and study timeline used to evaluate the feasibility, safety and tolerability of administering low dose estrogen and/or a probiotic to premenopausal African, Caribbean, and Black (ACB) women. Eligible participants were randomized in a 1:1:1:1 ratio to receive one of four interventions including 1) the Estring alone 2) the Estring in combination with the probiotic L. rhamnosus GR-1 and L. reuteri RC-14 RepHresh Pro-B (administered vaginally), 3) the Estring together with the RepHresh Pro-B (administered orally) or the RepHresh (administered vaginally) alone. The duration of the intervention was 30 days with a 7-day follow up (visit 5) safety check. The study was designed to compare outcomes in each woman at baseline (visit 2) to the end of treatment (visit 4) with each participant serving as their own control.CC BY · PubMed Central
Fig 3 Intervention protocol adherence. Adherence was determined for Estring and probiotic intervention protocols (IP) both individually and overall. The bar plots indicate adherence for all participants who received the intervention including those who prematurely terminated the study. Women who did not complete the protocol were considered as nonadherent and assigned a value of zero. Each data point represents a participant, and the bars depict the median ± IQR. A. Overall participants showed a high adherence to the study protocols regardless of the study. B-C. Similarly, participants demonstrated high adherence for both Estring and probiotic administration with no significant differences observed between intervention type or route of probiotic administration.
Fig 3 Intervention protocol adherence. Adherence was determined for Estring and probiotic intervention protocols (IP) both individually and overall. The bar plots indicate adherence for all participants who received the intervention including those who prematurely terminated the study. Women who did not complete the protocol were considered as nonadherent and assigned a value of zero. Each data point represents a participant, and the bars depict the median ± IQR. A. Overall participants showed a high adherence to the study protocols regardless of the study. B-C. Similarly, participants demonstrated high adherence for both Estring and probiotic administration with no significant differences observed between intervention type or route of probiotic administration.CC BY · PubMed Central
Fig 4 Adverse events (AEs). A total of 88 AEs were reported by 37 participants for each intervention. This bar plot summarizes the types of AEs based on their reported frequency and intensity. AEs reported with a mild intensity are represented in green while a moderate intensity is indicated in orange and severe AEs are highlighted in red. The number of reports according to event type is outlined based on the frequency of reports. Most reported AEs were mild (66/88; 75%), with only 7% (6/88) showing a severe intensity and no serious AEs (SAEs) reported. Vaginal irritation/itching/burning followed by cramps/abdominal pain were the most frequently reported AEs. In additional most AEs were short lived and non-recurring with 7% (6/88) ongoing after study completion.
Fig 4 Adverse events (AEs). A total of 88 AEs were reported by 37 participants for each intervention. This bar plot summarizes the types of AEs based on their reported frequency and intensity. AEs reported with a mild intensity are represented in green while a moderate intensity is indicated in orange and severe AEs are highlighted in red. The number of reports according to event type is outlined based on the frequency of reports. Most reported AEs were mild (66/88; 75%), with only 7% (6/88) showing a severe intensity and no serious AEs (SAEs) reported. Vaginal irritation/itching/burning followed by cramps/abdominal pain were the most frequently reported AEs. In additional most AEs were short lived and non-recurring with 7% (6/88) ongoing after study completion.CC BY · PubMed Central
Fig 5 Safety blood markers. Blood collected at baseline (visit 2) and at the end of the intervention (visit 4) was used to measure metabolic, lipid and complete blood count panels pre and post intervention to evaluate safety. The safety blood marker panel consisted of 12 markers depicted by representative dot plots to monitor changes in health. Each data point is representative of a participant which has a paired sample taken at visit two and four. The four colours black, orange, blue, and red in each graph represent the treatment arm of each participant. In addition, the dotted lines in each graph indicate the clinically relevant thresholds representative of a healthy reference range for each safety marker. Overall, no clinically significant change was observed pre and post intervention suggesting that 30 days of the Estring© and/or probiotic RepHresh™ Pro-B™ does not induce changes to overall health. Moreover, the data is evenly distributed across intervention arms and thereby does not indicate an association to the type of intervention.
Fig 5 Safety blood markers. Blood collected at baseline (visit 2) and at the end of the intervention (visit 4) was used to measure metabolic, lipid and complete blood count panels pre and post intervention to evaluate safety. The safety blood marker panel consisted of 12 markers depicted by representative dot plots to monitor changes in health. Each data point is representative of a participant which has a paired sample taken at visit two and four. The four colours black, orange, blue, and red in each graph represent the treatment arm of each participant. In addition, the dotted lines in each graph indicate the clinically relevant thresholds representative of a healthy reference range for each safety marker. Overall, no clinically significant change was observed pre and post intervention suggesting that 30 days of the Estring© and/or probiotic RepHresh™ Pro-B™ does not induce changes to overall health. Moreover, the data is evenly distributed across intervention arms and thereby does not indicate an association to the type of intervention.CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 1 Not valid · 2 Not checked · 21 Own results and interpretations

2 more claims

Create a free account to see all 32 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 61 references

Research works printed but not linked: 1

  1. MR Orazov, 2020, Combination local therapy for genitourinary syndrome of menopause: treatment perspectives, Gyn and Rep End & Metab, 1, 113

Cited by

See all 5

Metadata

Authors
Gill, B., Wessels, J. M., Hayes, C. L., Ratcliffe, J., Wokuri, J., Ball, E., Reid, G., Kaul, R., Rana, J., Alkhaifi, M., Tharao, W., Smaill, F., & Kaushic, C.
Affiliations
  • McMaster University (CA)
  • Women's Health In Women's Hands (CA)
  • Western University (CA)
  • University Health Network (CA)
  • Michael G. DeGroote Institute for Infectious Disease Research (CA)
Corresponding author
  • Smaill, Fiona
  • Kaushic, Charu
Venue
PLoS ONE
Published
2025-01-21
Volume
20
Issue
1
Pages
e0315576
ISSN
1932-6203 (ISSN-L)
OpenAlex
W4406657430
Cited by
5
References
61
Citations by year
2026: 2 · 2025: 3
FWCI
2.72
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Canadian Institutes of Health Research (FRN#181875, FRN#154047, FRN#159229)
  • CIHR HIV Clinical Trials Network
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
estradiol, vaginal probiotics, vaginal microbiota, bacterial vaginosis, HIV-1 susceptibility, premenopausal women, feasibility and safety, student retention, adverse events, HIV prevention
MeSH terms
Caribbean People, Administration, Intravaginal, Adolescent, Adult, Canada, Estrogens, Feasibility Studies, Female, Humans, Middle Aged, Pilot Projects, Vagina, HIV Infections, Vaginosis, Bacterial, Probiotics, Black People, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial. https://app.cochat.ai/papers/10.1371/journal.pone.0315576
The paper
Gill, B., Wessels, J. M., Hayes, C. L., Ratcliffe, J., Wokuri, J., Ball, E., Reid, G., Kaul, R., Rana, J., Alkhaifi, M., Tharao, W., Smaill, F., & Kaushic, C. (2025). Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial. PLoS ONE. https://doi.org/10.1371/journal.pone.0315576

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.